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Interleukin-6 increases the 
expression and activity of insulin-
degrading enzyme
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Impairment of the insulin-degrading enzyme (IDE) is associated with obesity and type 2 diabetes 
mellitus (T2DM). Here, we used 4-mo-old male C57BL/6 interleukin-6 (IL-6) knockout mice (KO) to 
investigate the role of this cytokine on IDE expression and activity. IL-6 KO mice displayed lower 
insulin clearance in the liver and skeletal muscle, compared with wild type (WT), due to reduced IDE 
expression and activity. We also observed that after 3-h incubation, IL-6, 50 and 100 ng ml−1, increased 
the expression of IDE in HEPG2 and C2C12 cells, respectively. In addition, during acute exercise, the 
inhibition of IL-6 prevented an increase in insulin clearance and IDE expression and activity, mainly in 
the skeletal muscle. Finally, IL-6 and IDE concentrations were significantly increased in plasma from 
humans, after an acute exercise, compared to pre-exercise values. Although the increase in plasma IDE 
activity was only marginal, a positive correlation between IL-6 and IDE activity, and between IL-6 and 
IDE protein expression, was observed. Our outcomes indicate a novel function of IL-6 on the insulin 
metabolism expanding the possibilities for new potential therapeutic strategies, focused on insulin 
degradation, for the treatment and/or prevention of diseases related to hyperinsulinemia, such as 
obesity and T2DM.
Interleukin-6 (IL-6) is a pleiotropic cytokine with several functions in different tissues1. Initially, IL-6 was 
described as an important factor of the immune system2. However, it has been shown that this cytokine also plays 
an important role in metabolic regulation3, especially on glucose homeostasis4.
Insulin is one of the most important hormones in glucose homeostasis, and its action depends on its secretion, 
the sensitivity of target tissues, and clearance. There are several studies regarding the effects of IL-6 on insulin 
sensitivity5,6 and secretion7,8; however, studies concerning its function on insulin clearance are scarce.
Insulin clearance occurs mainly in the liver, primarily by the action of insulin-degrading enzyme (IDE)9. This 
enzyme, a 110 kDa zinc-metalloprotease, was initially identified as an insulin degrading enzyme10. Subsequently, 
it was found that IDE also degrades other amyloidogenic peptides, such as amyloid β 11. Impairment of IDE are 
closely related to the development of diseases, such as type 2 diabetes mellitus (T2DM)12,13 and Alzheimer’s dis-
ease (AD)14. Also, it is proposed that IDE malfunction could be the link between these two pathologies15.
Selective modulators of IDE activity could work as potential drugs for treatment of T2DM and AD16. While 
IDE activators have been proposed as AD therapies17, it is uncertain if activation of this enzyme would be the 
better therapeutic approach for T2DM. To the contrary, treatment with IDE inhibitors seems to potentiate insulin 
signaling18 and a fast and short pre-meal IDE inhibition could be useful for T2DM therapy19. However, despite 
increasing insulin signaling, acute IDE inhibition impaired glucose tolerance in mice, casting a shadow on the 
usefulness of the IDE inhibition for the treatment of T2DM20. Interestingly, IDE knockout (KO) mice display 
chronic hyperinsulinemia21 that, over time, induces a reduction of insulin receptor expression, leading to insulin 
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resistance22. Also, downregulation of IDE, associated with hyperinsulinemia, is observed in obese and diabetic 
patients23,24, and rodents13,25. Therefore, we believe that finding molecules which are able to increase IDE function 
could be important for the development of new therapeutic strategies against diseases related to hyperinsuline-
mia, such as obesity and T2DM.
Some interventions25–27 and molecules28,29 can modulate the expression and activity of IDE. In this way, phys-
ical exercise increases IDE expression in the liver and skeletal muscle of rodents30, and this could explain the 
augmentation of insulin clearance observed in these rodents and humans31. It is also known that the ciliary neu-
rotrophic factor (CNTF), a member of the IL-6 family of cytokines, can also modulate insulin clearance and IDE 
expression in the liver of Swiss mice and in HEPG2 cells32. Thus, we hypothesized that IL-6 likewise could have 
an effect on insulin degradation.
Here, we demonstrate that IL-6 deficient mice displayed reduced insulin clearance, probably due to lower IDE 
action in the liver and skeletal muscle. In addition, IL-6 incubation increased the expression of IDE in HEPG2 
and C2C12 cells. We also found that, during acute endurance exercise, IL-6 mediated the increase of IDE expres-
sion and activity, mainly in the skeletal muscle, increasing insulin clearance, a phenomenon that may also occur 
in humans.
Results
IL-6 KO mice displayed altered metabolic parameters. KO mice showed a significant reduction 
of IL-6 content in plasma, liver, and skeletal muscle, confirming the deficiency of this cytokine in these mice 
(Suppl Fig. 1). KO mice also displayed a reduction in the body and skeletal muscle weight, despite an augmented 
adiposity, compared with wild type (WT) mice. In addition, a decreased insulinemia and increased glycemia was 
observed in the KO group (Table 1).
IL-6 KO mice had impaired glucose, but not insulin, tolerance. IL-6 plays an important role on 
glucose metabolism4,33. Here, we observed an impaired glucose tolerance in KO mice (Fig. 1A and B), without a 
change in insulin tolerance (Fig. 1C and D), compared with WT mice. In addition, the Akt phosphorylation in 
the liver and skeletal muscle (Fig. 1E and F) was similar between KO and WT groups.
IL-6 KO mice displayed decrease of insulin secretion and clearance. During the ipGTT, KO mice 
displayed decreased plasma C-peptide concentration (Fig. 1G and H), indicating impairment of insulin secretion. 
This observation was confirmed by a significant reduction in glucose-stimulated insulin secretion in isolated 
pancreatic islets from KO mice (Fig. 1M). Interestingly, the insulinemia was not reduced at the same extent than 
plasma C-peptide, during the ipGTT (Fig. 1I and J). Thus, the C-peptide/insulin ratio was reduced in the KO 
mice (Fig. 1K and L), indicating that insulin clearance was also decreased. A higher concentration of insulin was 
registered at 60 min of the ipITT, in the KO mice (Fig. 1O), indicating a reduction of insulin clearance in these 
mice, although no significantly difference was observed in the area under curve (AUC) of plasma insulin between 
groups (Fig. 1P).
IL-6 KO mice had reduced IDE expression and activity in the liver and skeletal muscle. IDE 
is the main enzyme responsible for insulin degradation9. Corroborating the reduced insulin clearance in the 
KO mice, IDE gene expression (Fig. 2A and B), protein content (Fig. 2C and D), and activity (Fig. 2E–H) were 
decreased in the liver and skeletal muscle, compared with WT mice.
IL-6 increased IDE expression in HEPG2 and C2C12 cells. In the following set of experiments, HEPG2 
and C2C12 cells were incubated, for 3-h, at different concentrations of IL-6. The IDE protein content was signifi-
cantly increased in HEPG2 and C2C12 cells, at 50 and 100 ng ml−1 IL-6, respectively (Fig. 3A and B).
IL-6 inhibition impaired the increase on insulin clearance in mice, after an acute endurance 
exercise. Since a substantial amount of IL-6 is released in the plasma during skeletal muscle contractions 
(Supple Fig. 2), we investigated the role of this cytokine on insulin clearance, after acute exercise. During ipITT, 
we observed that inhibition of IL-6 increased insulin tolerance in EXE + TCZ (exercised mice treated with tocili-
zumab, a pharmacological IL-6 receptor neutralizing antibody), and this increase was bigger than in the exercised 
(EXE) mice, as judged by the AUC of blood glucose (Fig. 4A and B). Interestingly, the higher insulin tolerance 
was accompanied by higher levels of plasma insulin during the ipITT, indicating a lower insulin clearance in the 
EXE + TCZ mice, compared with EXE mice (Fig. 4C and D).
Parameters WT KO
Body weight (g) 28.64 ± 0.49 24.79 ± 0.31*
Skeletal muscle pad (% of body weight) 1.139 ± 0.026 1.057 ± 0.016*
Fat pad (% of body weight) 1.046 ± 0.13 1.741 ± 0.11*
Fasting blood glucose (mg dl−1) 73.86 ± 4.10 92.29 ± 3.69*
Fasting plasma insulin (ng ml−1) 0.265 ± 0.051 0.120 ± 0.009*
Table 1.  Metabolic parameters of the IL-6 KO mice. *p ≤ 0.05 vs WT.
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IL-6 inhibition impaired IDE expression and activity in the skeletal muscle of mice, after an 
acute endurance exercise. We also evaluated the IDE expression and activity in exercised mice, treated 
with an IL-6 inhibitor. Corroborating the insulin clearance data, a single bout of exercise increased IDE gene 
expression in the liver and skeletal muscle (Fig. 5A and B), but IDE protein expression increased only in the 
skeletal muscle of EXE mice, compared with CTL mice (Fig. 5C and D). No alteration was found in IDE activity, 
after acute exercise (Fig. 5E–H). Interestingly, IL-6 inhibition prevents an increase in the expression of the IDE 
gene in liver and skeletal muscle (Fig. 5A and B), and IDE protein expression only in the skeletal muscle (Fig. 5C 
and D). We also observed reduced IDE activity in the skeletal muscle of EXE + TCZ mice, compared with EXE 
mice (Fig. 5F and H).
Figure 1. Glucose and insulin metabolism in the IL-6 KO mice. Blood glucose (A) and AUC of blood glucose 
(B) before (0 min) and 15, 30, 60 and 120 min after administration of 1 g kg−1 glucose, n = 6. Blood glucose 
(C) and AUC of blood glucose (D) before (0 min) and 5, 10, 15, 20, 25, 30 and 60 min after administration 
of 0.75 U kg−1 insulin, n = 6. Immunoblotting of AKT phosphorylated at serine 473 with (+ ) or without 
(− ) administration of 10 U insulin per mouse, in the liver (E) and gastrocnemius muscle (F), n = 4. Plasma 
C-peptide (G), insulin (I) and C-peptide/insulin ratio (K), during ipGTT, and its respective AUCs (H,J and 
L), n = 4. Insulin secretion in isolated pancreatic islets stimulated with 2.8, 5.8, 11.2 and 22.4 mmol l−1 glucose 
(M). Total insulin content of islets (N), n = 7. Plasma insulin concentration (O) and AUC of plasma insulin (P), 
during ipITT, n = 6. WT, wild type mice; and KO, IL-6 knockout mice. Data are presented as the mean ± S.E.M. 
*p ≤ 0.05 vs WT.
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Figure 2. Expression and activity of IDE in the liver and skeletal muscle from IL-6 KO mice. mRNA 
expression of IDE in the liver (A) and gastrocnemius muscle (B), n = 6. Protein expression of IDE in the liver 
(C) and gastrocnemius muscle (D) and its representative immunoblottings images, n = 5. Kinetic of IDE activity 
assay in liver (E) and in gastrocnemius (F) of mice, n = 5–6. Fluorescent intensity at Ex/Em = 490/520 nm was 
continuously recorded, every 5 min, during 60 min. 5-FAM concentration was calculated using a standard curve 
and normalized per μ g of total protein. IDE activity was calculated as described27 and normalized per μ g of total 
protein in the liver (G) and gastrocnemius (H) of mice, n = 5–6. WT, wild type mice; and KO, IL-6 knockout 
mice. Data are presented as the mean ± S.E.M. *p ≤ 0.05 vs WT.
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Figure 3. Effects of IL-6 incubation on IDE protein expression in HEPG2 and C2C12 cells. Protein 
expression of IDE in HEPG2 (A) and C2C12 (B) cells and its representative immunoblottings images. The cells 
were incubated at 0, 10, 50 and 100 ng ml−1 IL-6, during 3 h. Data are presented as the mean ± S.E.M. n = 3–4. 
*p ≤ 0.05 vs 0 ng ml−1 IL-6.
Figure 4. Effect of IL-6 inhibition on insulin tolerance and clearance after acute exercise in mice. Blood 
glucose (A) and AUC of blood glucose (B) before and 5, 10, 15, 20, 25, 30 and 60 min after administration of 
0.75 U kg−1 insulin. Plasma insulin (C) and AUC of plasma insulin (D) at 0, 5, 15, 30 and 60 min during ipITT. 
CTL, control mice; EXE, exercised mice; and EXE + TCZ, exercised mice treated with 2 mg kg−1 Tocilizumab 
1-h before the exercise protocol. Data are presented as the mean ± S.E.M. n = 6. *p ≤ 0.05 vs CTL and #p ≤ 0.05 
vs EXE.
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Figure 5. Effects of IL-6 inhibition on IDE expression and activity in the liver and skeletal muscle of mice 
after acute exercise. mRNA expression of IDE in the liver (A) and gastrocnemius muscle (B), n = 5–6. Protein 
expression of IDE in the liver (C) and gastrocnemius muscle (D) and its representative immunoblottings images, 
n = 5–6. Kinetic of IDE activity assay in liver (E) and gastrocnemius (F), n = 5. Fluorescent intensity at Ex/
Em = 490/520 nm was continuously recorded, every 5 min, during 60 min. 5-FAM concentration was calculated 
using a standard curve and normalized per μ g of total protein. IDE activity was calculated as described27 and 
normalized per μ g of total protein in the liver (G) and gastrocnemius (H) of mice, n = 5. CTL, control mice; 
EXE, exercised mice; and EXE + TCZ, exercised mice treated with 2 mg kg−1 Tocilizumab 1-h before the acute 
exercise protocol. Data are presented as the mean ± S.E.M. *p ≤ 0.05 vs CTL and #p ≤ 0.05 vs EXE.
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IL-6 was positively correlated with IDE protein expression and activity in the plasma of humans 
subjects, after an acute endurance exercise. Finally, we measured IL-6 concentration, IDE protein 
expression and activity in the plasma of human subjects, before and after acute exercise. Plasma IL-6 and IDE 
concentrations were significantly increased post-exercise, compared with pre-exercise group (Fig. 6A and B), and 
a positive correlation between these two plasmatic parameters was confirmed (Fig. 6E). Although the increase of 
IDE activity, in the post-exercise group, was not statistically significant compared with pre-exercise (Fig. 6C and D), 
this plasmatic parameter was also positively correlated with IL-6 concentration (Fig. 6F).
Discussion
Impaired IDE expression and/or activity are closely related to diseases associated with hyperinsulinemia, such 
as obesity and T2DM12. Therefore, increasing the function of IDE could be a strategy for the treatment of these 
pathologies. Here, we found that exposure to IL-6 increased IDE protein expression in HEPG2 and C2C12 cells. 
Figure 6. IL-6 concentration and IDE protein expression and activity in the plasma of human subjects, 
before and after acute endurance exercise. Plasma IL-6 concentration (A), n = 5. IDE protein expression 
and its representative immunoblotting image (B), n = 5. Kinetic of IDE activity assay in the plasma (C), 
n = 5. Fluorescent intensity at Ex/Em = 490/520 nm was continuously recorded, every 5 min, during 60 min. 
5-FAM concentration was calculated using a standard curve and normalized per μ g of total protein. Total 
IDE activity (D) was calculated as described27 and normalized per μ g of total protein, n = 5. Data represent 
the mean ± S.E.M. *p ≤ 0.05 vs PRE-EXE. Correlation between plasma IL-6 concentration and IDE protein 
expression (E) or IDE activity (F), n = 10. The Pearson product moment correlation coefficient (r) was 
determined using the software GraphPad Prism 5. PRE-EXE, plasma samples of human subjects before acute 
endurance exercise; and POST-EXE, plasma samples of human subjects 3-h after acute exercise (30-min cycling 
at 70% of VO2peak).
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We also observed that IL-6 KO mice displayed reduced insulin clearance, probably due to lower IDE function in 
the liver and skeletal muscle. Finally, we demonstrated that during acute exercise, IL-6 release seems to be nec-
essary to increase IDE expression and activity, mainly in the skeletal muscle of mice, an effect that likely occurs 
also in humans.
IL-6 is an interesting cytokine with a dual effect on glucose homeostasis. Initially, it was thought that this 
cytokine has deleterious effects on glucose homeostasis by impairing the insulin signaling, leading to insulin 
resistance6. Later, it was found that the loss of IL-6, not only failed to protect against these deleterious effects, but 
also induced glucose intolerance leading to development of mature-onset obesity34. These data show that IL-6 is 
important for the maintenance of normal carbohydrate and lipid metabolism. Indeed, here, 4-mo-old IL-6 KO 
mice developed glucose intolerance (Fig. 1A and B) and increased fat pad weight (Table 1), although impairment 
in insulin signaling and overweight were not observed. These last alterations were registered in older (9-mo-old) 
IL-6 deficient mice34. Although young IL-6 KO mice do not have impaired insulin sensitivity (Fig. 1C and D), 
they display reduced glucose-stimulated insulin secretion (Fig. 1M), which could explain the glucose intolerance 
during ipGTT. These data suggest that the impairment of insulin secretion and/or clearance precede the onset of 
insulin resistance in IL-6 KO mice.
The role of IL-6 on insulin secretion has been extensively studied, and there is substantial evidence that this 
cytokine increases insulin secretion7,8, and this increase seems to depend on the activation of the phospholipase 
C (PLC) - inositol triphosphate (IP3) dependent pathway8. However, further investigation demonstrated that 
IL-6 enhances insulin release also by increasing the glucagon-like peptide 1 (GLP-1) secretion from L cells and 
pancreatic α cells7.
While several studies have investigated the function of IL-6 on insulin secretion, its participation on insulin 
clearance was neglected. Here, we provide evidence that IL-6 must be essential to enhance insulin clearance prob-
ably by increasing IDE expression and activity in the liver and skeletal muscle. These are opposite effects from 
those reported for CNTF, a member of the IL-6 family of cytokines32. Although these two cytokines act through 
activation of glycoprotein 130 (gp 130), there are some peculiarities in their receptors35 that could explain these 
different effects on insulin clearance and IDE expression.
It is known that increase of adiposity is associated with decrease of IDE expression and insulin clearance, as 
observed in obesity25,36. Here, we show that IL-6 KO mice had an increased fat pad weight which could explain the 
reduced IDE expression and activity in these mice. However, to prove that this IDE modulation is an effect of IL-6 
loss, we treated this KO mice with 200 ng IL-6 during 3 days before the experiments. Interestingly, IL-6 treatment 
restored IDE gene expression of KO mice, without any alteration in the fat pad weight (see Supple Fig. 3). These 
data, associated with the results from in vitro experiments, confirm the important role of IL-6 on IDE modulation.
During physical exercise, muscle contractions release and increase the concentration of IL-6 in the blood-
stream, and this myokine37 modulates glucose homeostasis. Previous data suggest that the primary function of 
IL-6 during exercise is to maintain glucose turnover4. At the same time that IL-6 favors insulin to stimulate glu-
cose uptake by the skeletal muscle38, it increases glucose production in the liver39 to sustain the high demand for 
glucose by the former tissue. Although controversial40, it has been reported that, during exercise, this myokine 
could improve insulin sensitivity41. However IL-6 has been found to increase insulin secretion after exercise7 
whereas a reduction in plasma insulin was observed42. Here we proposed that IL-6 could also increase insulin 
clearance and IDE expression, induced by exercise, as reported30. Interestingly, we confirmed our hypothesis 
showing that inhibition of IL-6 signaling during acute endurance exercise blocks the augmentation of insulin 
clearance and IDE expression, mainly in the skeletal muscle. This phenomenon seems to be important to avoid a 
hazardous decrease of glycemia during exercise, making it more effective and safe.
Physical exercise is one of the first clinical approaches to prevent and treat metabolic diseases, such as obesity 
and T2DM. However, adherence to physical activity by obese and diabetic patients is very low43. Thus, finding 
alternatives for physical exercise would be useful for the prevention and treatment of these diseases. In this sce-
nario, IL-6 has been suggested as a promising candidate44. Here, we found that, as in mice, IL-6 seemed to have 
the same effects on insulin clearance in humans after acute endurance exercise, since the concentration of this 
myokine positively correlated with IDE expression in the plasma of these subjects. Although considering IL-6 
as a promising alternative to physical exercise, treatment with this cytokine may be not recommended due to its 
dual effects on glucose metabolism. Thus, find the mechanism activated by IL-6 during exercise, could help us to 
develope a safer exercise mimetic.
IL-6 may act on its target cells by canonical and non-canonical pathways. The canonical pathway is 
well-established and comprises the activation of the signal transducer and activator of transcription 3 (STAT3), 
which, in the nucleus, enhances the transcription of several genes45,46. The non-canonical pathway refers to the 
activation of the 5′ -adenosine monophosphate-activated protein kinase (AMPK). Even though the non-canonical 
pathway remains poorly understood, it was reported that IL-6 directly activates AMPK through increas-
ing cyclic adenosine monophosphate (cAMP) and AMP/ATP ratio in skeletal muscle of rats47. Since IL-6 KO 
mice show reduced activation of AMPK48, we speculate that this non-canonical pathway could be the mecha-
nism whereby IL-6 increases IDE expression. Moreover, we previously demonstrated that the treatment with 
5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) increased IDE expression in C2C12 cells30, cor-
roborating our hypothesis. However, this data does not exclude the possible role of STAT3 on IDE expression. 
Therefore, further investigations are necessary to clarify this matter.
In summary, here we described a novel function of IL-6 on glucose homeostasis, which consists of increase 
insulin clearance, probably due to augmentation of IDE expression and activity in the liver and skeletal muscle. 
In addition, we demonstrated that, after acute endurance exercise, IL-6 mediated the increase of IDE, mainly in 
the skeletal muscle of mice, an effect that seems to occur also in humans. Our findings expand the possibilities for 
new potential therapeutic strategies, focused on insulin degradation, that could be used in the treatment and/or 
prevention of diseases related to hyperinsulinemia, such as obesity and T2DM.
www.nature.com/scientificreports/
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Methods
Animals. The 4-mo-old males C57BL/6 wild type (WT) and IL-6 knockout (KO) mice were maintained on a 
12-h light/12-h dark cycle with controlled temperature and humidity during the entire experiment. All mice were 
allowed to feed (standard chow diet) and drink tap water ad libitum. After the experiments using WT and KO 
mice, other males C57BL/6 WT mice were distributed into three different groups: control (CTL), exercised (EXE) 
and exercised mice treated with 2 mg kg−1 tocilizumab (a pharmacological IL-6 receptor neutralizing antibody) 
1-h before the exercise protocol (EXE + TCZ).
Maximum oxygen consumption (VO2 max) and acute endurance exercise protocol in mice. 
Before the acute exercise protocol, we measured the VO2 max in all mice from the CTL, EXE and EXE + TCZ 
groups, as described before30. After 10 days, mice from EXE and EXE + TCZ groups were submitted to a single 
bout of exercise on a treadmill inclined at 25° for 3-h at 60–70% of VO2 max. All measurements made in these 
mice were performed immediately after the acute exercise.
Intraperitoneal glucose and insulin tolerance tests (ipGTT and ipITT). The ipGTT and ipITT was 
performed as previously described27. The blood glucose concentration was measured by tail bleed using glu-
cose strips on Accu-Chek Performa II glucometer (Roche, Sao Paulo, Brazil). During the ipGTT, blood samples 
were collected from the tail before (0 min) and 15 and 30 min after glucose administration. The plasma samples 
was obtained by centrifugation (1100 g for 15 min at 4 °C) and was stored at − 80 °C for posterior insulin and 
C-peptide quantification.
In vivo insulin clearance test. During the ipITT, blood samples were collected before (0 min) and 15, 30 
and 60 min after insulin administration to determine the plasma insulin concentrations25.
Plasma C-peptide and insulin concentration. Plasma C-peptide was measured by Rat/Mouse C-Peptide 
2 ELISA Kit (Cat. EZRMCP2-21K, EMD Millipore), following the manufacturer’s instructions, and plasma insu-
lin concentration was determined by radioimmunoassay (RIA), as described49.
Tissue samples. The mice were killed in a CO2-saturated chamber followed by beheading. Liver and gas-
trocnemius skeletal muscle samples from the mice were collected, snap-frozen in liquid nitrogen, and stored 
at − 80 °C for subsequent experiments (RT-PCR Real time, Western blot and IDE activity). The pancreatic islets 
isolation was performed as previously described50.
Glucose-stimulated insulin secretion in pancreatic islets. The islets were pre-incubated for 1-h in 
Krebs-Henseleit buffer solution (KHBS) containing 0.5 g l−1 bovine serum albumin (BSA) and 5.6 mmol l−1 glu-
cose (95% O2, 5% CO2, pH 7.4, 37 °C). Subsequently, we incubate five islets per well for an additional hour in the 
KHBS containing 2.8, 5.6, 11.2 or 22.4 mmol l−1 glucose. The supernatant was collected to evaluate the insulin 
secretion, and the islets were homogenized in an alcohol/acid solution to measure the total insulin content by 
RIA.
Real time RT- PCR. Tissues samples of liver and skeletal muscle was homogenized in 1 ml TRIzol® 
Reagent (Cat. 15596026, Invitrogen™ , Thermo Fisher Scientific Inc, Waltham, MA, USA), and the total 
mRNA was extracted following the manufacturer’s instructions. To prepare the cDNA, we used 1 μ g of total 
mRNA and High-Capacity cDNA Reverse Transcription Kit (Cat. 4368814, Applied Biosystems™ , Thermo 
Fisher Scientific Inc, Waltham, MA, USA). Real time PCR was performed on 7500 Fast Real-time PCR System 
(Applied Biosystems™ ) using Fast SYBR® Green Master Mix (Cat. 4385612, Applied Biosystems™ ). Mice 
IL-6 and IDE gene expression was measured and GAPDH was used as housekeeping gene (IL-6 forward 
5′ -CACGGCCTTCCCTACTTCAC-3′ and reverse 5′ -GGTCTGTTGGGAGTGGTATC-3′ ; IDE forward 
5′ -CTGTGCCCCTTGTTTGATGC-3′ and reverse 5′ -GTTCCCCGTAGCCTTTTCCA-3′ ; GAPDH forward 
5′ -CCTGCACCACCAACTGCTTA-3′ and reverse 5′ -GCCCCACGGCCATCACGCCA-3′ ). Real-time PCR data 
were analyzed using the 7500 Software version 2.0.5 (Applied Biosystems™ ).
Western Blot. For protein extraction, tissue samples of liver and skeletal muscle, were homogenized in a lysis 
buffer containing 10 mmol l−1 EDTA, 100 mmol l−1 Tris base, 100 mmol l−1 sodium pyrophosphate, 100 mmol l−1 
sodium fluoride, 10 mmol l−1 sodium orthovanadate, 2 mmol l−1 Phenylmethylsulfonyl fluoride, 1% Triton X-100 
and 1 μ g ml−1 aprotinin. Protein concentration of the samples was determined using Bradford reagent (Cat. 
500-0006 N, BioAgency Biotecnologia, São Paulo, Brazil). After, 30 μ g protein samples were homogenized and 
boiled (5 min at 100 °C) in a Laemmli buffer, applied on 10% SDS-PAGE (sodium dodecyl sulfate polyacryla-
mide gel electrophoresis), and transferred to nitrocellulose membranes. These membranes were blocked in a 
Tris-buffered saline (10 mmol l−1 Tris base, 150 mmol l−1 NaCl and 0.25% (vol./vol.) of Tween 20) containing 
5% (wt./vol.) BSA for 1-h at room temperature. After, the membranes were incubated overnight at 4 °C with 
primary antibodies (anti-phospho-Aktser473, Santa Cruz Biotechnology cat. sc-7985; anti-IDE, Abcam cat. 
ab32216; anti-GAPDH, Sigma cat. G9545). Bands detection was performed by chemiluminescence (SuperSignal 
West Fento, Pierce Biotechnology Inc., Rockford, IL, USA) after incubation with an appropriated horseradish 
peroxidase-conjugated secondary antibody, and the bands were visualized using the Amersham Imager 600 (GE 
Healthcare Life Sciences, Pittsburgh, PA, USA). Band intensities were analyzed using ImageJ software (National 
Institutes of Health, Maryland, USA).
HEPG2 and C2C12 cells culture. HEPG2 (a human liver carcinoma cell line) and C2C12 (a mouse myo-
blast cell line) cells were culture as described before30. For the differentiation of C2C12 cells, we used DMEM 
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high glucose containing 2% (vol./vol.) horse serum, and we culture it in this medium for 5 days. HEPG2 and 
differentiated C2C12 cells were incubated at 0, 10, 50 or 100 ng ml−1 IL-6 (Cat. PMC0061, Gibco™ , Thermo 
Fisher Scientific Inc, Waltham, MA, USA) for 3-h. The cells were collected in trypsin/EDTA solution, washed 
with phosphate-buffered saline (PBS), and then homogenized in a urea anti-protease/anti-phosphatase buffer, for 
subsequent analysis of IDE protein expression.
Plasma samples of human subjects. Plasma samples of human subjects were obtained from a previous 
study, and for all detailed information about this subjects (untrained healthy male) and experimental procedures, 
see ref. 51. The exercise protocol comprise a standardized warm-up period following by 30-min of cycling, at 70% 
of VO2peak. Blood samples were collected before (PRE-EXE) and 3-h after (POST-EXE) the exercise session for 
posterior analysis of IL-6 concentration, IDE protein expression and activity.
IDE activity assay. IDE activity, from tissues and plasma samples, was measured by SensoLyte® 520 IDE 
Activity Assay Kit (Cat. AS-72231, AnaSpec, Fremont, CA, USA), following the manufacturer’s recommenda-




×IDE activity A1 A0
T V
D
A1 is the concentration of 5-FAM at 60 min and A0 at 0 min; T is the total time of the assay (60 min); V is the 
volume of samples, and D is the dilution. The 5-carboxyfluorescein (5-FAM, the product of the enzyme reaction) 
concentration and the total IDE activity were normalized per μ g of total protein, which was determined using 
Bradford reagent.
Quantification of plasma IL-6 concentration. Plasma IL-6 concentrations were measured using Mouse 
IL-6 ELISA Kit (Cat. EZMIL6, Merck Millipore, Darmstadt, Germany) and Human IL-6 Quantikine® ELISA Kit 
(Cat. D6050, R&D Systems, Minneapolis, MN, USA), according to the manufacturer’s instructions.
Statistics. For the statistical analysis of two groups we used the Student’s t-test and for three or more groups, 
we performed the one-way ANOVA using the unpaired Tukey’s post-hoc test. The data are presented as the 
mean ± standard error mean (SEM) and all data were considered significantly different if p ≤ 0.05. The Pearson 
product moment correlation coefficient (r) was determined to examine the relationship between IL-6 concentra-
tion and IDE protein expression or activity in the plasma of human subjects.
Study approval. All experimental procedures made in mice and humans subjects were approved by the local 
ethics committee (approval numbers 3087-1 and 848.145). The animal experiments were conducted following to 
the last revision of the National Institutes of Health (NIH) guide for the care and use of laboratory animals. In 
the case of humans, the experimental procedures were explained to all subjects, who provided written informed 
consent before the study that was conducted according to the latest revision of the Declaration of Helsinki51.
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